Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan

被引：5

作者：

Bell, JM ^{[1
]}

Turnidge, JD

Inoue, M

Kohno, S

Hirakata, Y

Ono, Y

Jones, RN

机构：

[1] Womens & Childrens Hosp, Adelaide, SA, Australia

[2] Kitasato Univ, Sch Med, Kanagawa, Japan

[3] Nagasaki Univ, Sch Med, Nagasaki 852, Japan

[4] Teikyo Univ, Sch Med, Tokyo 173, Japan

[5] JONES Grp, JMI Labs, N Liberty, IA USA

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 02期

关键词：

in vitro activity; MDR; novel antimicrobial;

D O I：

10.1093/jac/dkh547

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：276 / 278

页数：4

共 11 条

[1]

[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th

[2] Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].

Apfel, CM ;

Locher, H ;

Evers, S ;

Takács, B ;

Hubschwerlen, C ;

Pirson, W ;

Page, MGP ;

Keck, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064

[3] Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756 [J].

Bell, JM ;

Turnidge, JD ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (02) :125-132

[4] High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa:: Results from SENTRY antimicrobial surveillance program, 1998-1999 [J].

Bell, JM ;

Turnidge, JD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :879-881

[5] Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents [J].

Credito, K ;

Lin, GR ;

Ednie, LM ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :4033-4036

[6] Antipneumococcal activity of LBM415, a new peptide diformylase inhibitor, compared with those of other agents [J].

Ednie, LM ;

Pankuch, G ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :4027-4032

[7] Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor [J].

Gross, M ;

Clements, J ;

Beckett, RP ;

Thomas, W ;

Taylor, S ;

Lofland, D ;

Ramanathan-Girish, S ;

Garcia, M ;

Difuntorum, S ;

Hoch, U ;

Chen, H ;

Johnson, KW .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (03) :487-493

[8] Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis [J].

Hasegawa, K ;

Chiba, N ;

Kobayashi, R ;

Murayama, SY ;

Iwata, S ;

Sunakawa, K ;

Ubukata, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1509-1514

[9] Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates [J].

Jones, RN ;

Fritsche, TR ;

Sader, HS .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 49 (01) :63-65

[10] Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates [J].

Jones, RN ;

Moet, GJ ;

Sader, HS ;

Fritsche, TR .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) :804-807

← 1 2 →